StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) stock

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.85+0.04 (+5.13%)

Close on Nov 18, 2026Market cap $109.79MP/E –Yield –

Organogenesis operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Organogenesis's operating income for the twelve months ending Jun 30, 2026 was -$35.87M. For fiscal 2025 it was $44.69M. The highest annual figure on record is $72.22M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.69M–
FY2024Dec 31, 2024-$1.28M-110.2%
FY2023Dec 31, 2023$12.53M-43.8%
FY2022Dec 31, 2022$22.30M-69.1%
FY2021Dec 31, 2021$72.22M+170.5%
FY2020Dec 31, 2020$26.70M–
FY2019Dec 31, 2019-$29.85M–
FY2018Dec 31, 2018-$51.56M–
FY2017Dec 31, 2017-$5.49M–
FY2016Dec 31, 2016-$8.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$50.99M–
Q1 FY2026Mar 31, 2026-$68.89M–
Q4 FY2025Dec 31, 2025$63.29M+519.3%
Q3 FY2025Sep 30, 2025$20.73M+232.1%
Q2 FY2025Jun 30, 2025-$12.58M–
Q1 FY2025Mar 31, 2025-$26.75M–
Q4 FY2024Dec 31, 2024$10.22M–
Q3 FY2024Sep 30, 2024$6.24M-22.5%
Q2 FY2024Jun 30, 2024-$13.89M-242.6%
Q1 FY2024Mar 31, 2024-$3.85M–
Q4 FY2023Dec 31, 2023-$1.27M-114.6%
Q3 FY2023Sep 30, 2023$8.05M+352.5%
Q2 FY2023Jun 30, 2023$9.75M-18.3%
Q1 FY2023Mar 31, 2023-$4.00M–
Q4 FY2022Dec 31, 2022$8.72M-55.9%
Q3 FY2022Sep 30, 2022$1.78M-89.1%
Q2 FY2022Jun 30, 2022$11.94M-49.4%
Q1 FY2022Mar 31, 2022-$128.00K-101.0%
Q4 FY2021Dec 31, 2021$19.75M-8.5%
Q3 FY2021Sep 30, 2021$16.26M-28.7%
Q2 FY2021Jun 30, 2021$23.59M–
Q1 FY2021Mar 31, 2021$12.62M–
Q4 FY2020Dec 31, 2020$21.59M–
Q3 FY2020Sep 30, 2020$22.80M–
Q2 FY2020Jun 30, 2020-$2.25M–
Q1 FY2020Mar 31, 2020-$15.08M–
Q4 FY2019Dec 31, 2019-$2.15M–
Q3 FY2019Sep 30, 2019-$8.27M–
Q2 FY2019Jun 30, 2019-$7.32M–
Q1 FY2019Mar 31, 2019-$12.12M–
Q4 FY2018Dec 31, 2018-$4.48M–
Q3 FY2018Sep 30, 2018-$10.07M–
Q2 FY2018Jun 30, 2018-$17.03M-782.4%
Q1 FY2018Mar 31, 2018-$19.98M–
Q4 FY2017Dec 31, 2017-$2.40M–
Q3 FY2017Sep 30, 2017-$2.62M–
Q2 FY2017Jun 30, 2017$2.50M–
Q1 FY2017Mar 31, 2017-$2.97M–
Q4 FY2016Dec 31, 2016-$1.30M–
Q3 FY2016Sep 30, 2016-$14.49K–

More Organogenesis figures

See a number that looks wrong?